Autologous Stem Cell Transplant in Lymphoma Using a Noncryopreserved Platform: An Adapted Sequential Conditioning Maintaining Dose Intensity Does not Affect Transplantation Outcomes-Reference-Cited by-同舟云学术

Autologous Stem Cell Transplant in Lymphoma Using a Noncryopreserved Platform: An Adapted Sequential Conditioning Maintaining Dose Intensity Does not Affect Transplantation Outcomes

Published:2023-07 Issue:7 Volume:23 Page:545-551
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Sarmiento Mauricio,Rojas Patricio,Gutierrez Catherine,Quezada Jacqueline,Jara Veronica,Campbell James,Maria Garcia,Jose ,VicenteSandoval ,Vergara Max,Triantafilo Nicolas,Ocqueteau Mauricio

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference13 articles.

1. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma;Appelbaum;Blood,1978

2. A review of autologous stem cell transplantation in lymphoma;Zahid;Curr Hematol Malig Rep,2017

3. Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma;Dahi;Bone Marrow Transplant,2019

4. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study;Musso;Bone Marrow Transplant,2010

5. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity;Noesslinger;Eur J Haematol,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation;BMC Cancer;2024-08-13